Cyclooxygenase-2 specific inhibitors: A revolution?;Inhibiteurs specifiques de la cyclooxygenase-2: Une revolution?

Presse Medicale

Volumn 28, Issue 22, 1999, Pages 1182-1187

  Berenbaum, F ^a  

^a Serv Rhumatologie et UPRES A 7079   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; UNCLASSIFIED DRUG; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERANCE; ENZYME INHIBITION; HUMAN; INFLAMMATION; PROSTAGLANDIN SYNTHESIS; REVIEW; STOMACH MUCOSA; CLASSIFICATION;

CYCLOOXYGENASE INHIBITORS; HUMANS;

EID: 0033583883     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971 ; 231:232-5.
2. Berenbaum F. Cyclooxygenases and cyclooxygenase inhibitors: is a new class of drugs in the making? Rev Rhum Engl Ed 1998 ; 65:634-40.
3. Samuelsson B, Goldyne M, Granstrom E, Hamberg M, Malmsten C. Prostaglandins and thromboxanes. Annu Rev Biochem 1978 ; 47:997.
4. Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994 ; 367:243-9.
5. Kurumbail RG, Stevens AM, Gierse JK et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996 ; 384:644-8.
6. Gierse JK, McDonald JJ, Hauser SD, Rangwala SH, Koboldt CM, Seibert K. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem 1996; 271:15810-14.
7. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner M. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nature Struct Biol 1996 ; 3:927-33.
8. Kalgutkar AS, Crews BC, Rowlinson SW, Garner C, Seibert K, Marnett LJ. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Nature 1998 ; 280:1268-70.
9. DeWitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci 1988 ; 85:1412-16.
10. Merlie JP, Fagan D, Mudd J, Needleman P. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). J Biol Chem 1988 ; 263:3550-3
11. Yokohama C, Tanabe T. Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Commun 1989 ; 165:888-94.
12. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993 ; 330:156-60.
13. Feng L, Sun W, Xia Y et al. Cloning of two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch Biochem Biophys 1993 ; 307:361-8.
14. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992 ; 89:7384-8.
15. Dubois RN, Abramson SB, Crofford L et al. Cyclooxygenase in biology and disease. FASEB J 1998 ; 12:1063-73.
16. Goppelt-Struebe M. Regulation of prostaglandin endoperoxide synthase (cyclooxygenase) isozyme expression. Prostaglandins Leukot Essent Fatty Acids 1995 ; 52:213-22.
17. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory S. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation of COX-2 and interleukin-6 in rat adjuvant arthritis. J Clin Invest 1996 ; 97:2672-9.
18. Amin AR, Attur M, Patel RN et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. J Clin Invest 1997 ; 99:1231-7.
19. Angel J, Berenbaum F, Le Denmat C, Nevalainen T, Masliah J, Fournier C. IL-1-induced prostaglandin E2 biosynthesis in human synovial cells involves the activation of cytosolic phospholipase A2 and cyclooxygenase-2. Eur J Biochem 1994 ; 226:125-31.
20. Crofford LJ, Wilder RL, Ristimaki AP et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest 1994 ; 93:1095-101.
21. Kang RY, Freire-Moar J, Sigal E, Chu CQ. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br J Rheumatol 1996 ; 35:711-8.
22. Sano H, Hla T, Maier JAM et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 1992 ; 89:97-108.
23. Siegle I, Klein T, Backman JT, Saal JG, Nusing RM, Fritz P. Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum 1998 ; 41:122-9.
24. Terlain B, Jouzeau JY, Gillet P, Lecomte T Netter P. Cyclooxygenase inductible : du nouveau sur les relations entre anti-inflammatoires non stéroidiens et inhibition de la synthèse de prostaglandines. Presse Med 1995 ; 24:491-6.
25. Frölich JC. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmocol Sci 1997 ; 18:30-4.
26. Furst DE. Are there differences among nonsteroidal antiinflammatory drugs? Arthritis Rheum 1994 ; 37:1-9.
27. Spangler RS. Cyclooxygenase 1 and 2 in rheumatic disease : implications for nonsteroidal anti-inflammatory drug therapy. Semin Arthritis Rheum 1996 ; 26:435-46.
28. Hawkey C, Kahan A, Steinbruck K et al. Gastrointestinal tolerability of the COX2 inhibitor, meloxicam, in osteoarthritis patients : the meloxicam large scale international study safety assessment (MELISSA). Br J Rheumatol 1998 ; 37:937-45.
29. Masferrer JL, Zweifel BS, Manning PT et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic Proc Natl Acad Sci USA 1994 ; 91:3228-32.
30. Seibert K, Zhang Y, Leahy K et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994 ; 91:12013-17.
31. Chan CC, Boyce S, Brideau C et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337 : a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and non human primate stomach. J Exp Pharmacol Ther 1995 ; 274:1531-7.
32. Hawkey CJ. COX-2 inhibitors. Lancet 1999 ; 353:307-14.
33. Simon LS, Lanza FL, Lipsky PE et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998 ; 41:1591-602.
34. Elder DJ, Paraskeva C. COX-2 inhibitors for colorectal cancer. Nat Med 1998 ; 4:392-3.
35. Oshima M, Dinchuk JE, Kargman SL et al. Suppression of intestinal polyposis in ApcD716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996 ; 87:803-9.
36. Pasinetti GM. Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. J Neurosci Res 1998 ; 54:1-6.
37. Eckmann L, Stenson WF, Savidge TC et al. Role of intestinal epithelial cells in the host secretory response to infection by invasive bacteria: bacterial entry induces epithelial prostaglandin H synthase-2 expression and prostaglandin E2 and F2a production. J Clin Invest 1997 ; 100:296-309.
38. Shigeta J, Takahashi S, Okabe S. Role of cyclooxygenase-2 in the healing of gastric ulcers in rats. J Pharmacol Exp Ther 1998 ; 286:1383-90.
39. Mizuno H, Sakamoto C, Matsuda K et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997 ; 112:387-97.
40. Romano M, Ricci V, Memoli A et al. Helicobacter pylon up-regulates cyclooxygenase-2 mRMA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro. J Biol Chem 1998 ; 273:28560-3.
41. Sawaoka H, Kawano S, Tsuji S et al. Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa. Prostaglandins Leukot Essent Fatty Acids 1998 ; 59:313-6.
42. Hendel J, Nielsen OH Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease. Am J Gastroenterol 1997 ; 92:1170-3
43. Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 1996 ; 98:2076-85.
44. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used non-steroidal antiinflammatory drugs. Am J Med 1998 ; 104:413-21.
45. Morham SG, Langenbach R, Loftin CD et al. Prostaglandin synthase 2 gene disruption causes several renal pathology in the mouse. Cell 1995 ; 83:473-82.
46. Dinchuk JE, Car BD, Focht RJ et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase-11. Nature 1995 ; 378:406-9.
47. Khan KN, Venturini CM, Bunch RT et al. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol Pathol 1998 ; 26:612-20.
48. O'Brien WF. The role of prostaglandins in labor and delivery. Clin Perinatol 1995 ; 22:973-84.
49. Clyman RI, Hardy P, Waleh N et al. Cyclooxygenase-2 plays a significant role in regulating the tone of the fetal lamb ductus artenosus. Am J Physiol 1999 ; 276:R913-21
50. Chakraborty I, Das SK, Wang J, Dey SK. Developmental expression of the cyclo-oxygenase-1 and cyclo-oxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids. J Mol Endocrinol 1996 ; 16:107-22.
51. Charpigny C, Reinaud P, Tamby JP et al. Expression of cyclooxygenase-1 and -2 in ovine endometrium during the estrous cycle and early pregnancy. Endocrinology 1997 ; 138:2163-71.
52. Lim H, Paria BC, Das SK et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997; 91:197-208.
53. Berenbaum F. Prescription d'un AINS en rhumatologie. Encycl Méd Chir (Elsevier, Paris), Akos Encyclopédie, Pratique de Médecine, 7-0905, 1998, 4 p.
54. Cashman JN. The mechanisms of action of NSAIDs in analgesia. Drugs 1996 ; 52:13-23.
55. Dray A, Urban L. New pharmacological strategies for pain relief. Annu Rev Pharmacol Toxicol 1996 ; 16:253-80.
56. Langenbach R., Morham SG., Tiano HF et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995 ; 83:483-92.
57. Smith CJ, Zhang Y, Koboldt CM et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 1998 ; 95:13313-18.
58. Seibert JL, Zweifel BS, Manning PT et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994 ; 91:3228-32.
59. Beiche F, Brune K, Geisslinger G, Goppelt-Struebe M. Expression of cyclooxygenase isoforms in the rat spinal cord and their regulation during adjuvant-induced arthritis. Inflamm Res 1998 ; 47:482-7.